New hope for tough lung cancer: experimental drug takes on KRAS mutation
NCT ID NCT07601048
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Phase 3 trial tests a new drug called HRS-7058 against other KRAS G12C inhibitors in 450 adults with advanced or metastatic non-small cell lung cancer that has a specific KRAS G12C mutation and has stopped responding to standard treatments. The study compares how well HRS-7058 works and its safety, aiming to find a better option for these patients.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- HRS-7058 (a KRAS G12C inhibitor)
- What this could lead to
- If successful, this could offer a new treatment option for people with a specific type of advanced lung cancer that has stopped responding to standard therapies.
- What could go wrong
- This is an early-stage Phase 3 trial, so results are not yet known. The new drug may not be more effective or safer than existing KRAS G12C inhibitors, and side effects are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for KRAS G12C-POSITIVE ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER PATIENTS WHO HAVE FAILED STANDARD TREATMENT are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Tianjin Medical University Cancer Institute and Hospital
Tianjin, Tianjin Municipality, 300060, China